| Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa S Alosaimy, AM Lagnf, T Morrisette, MR Scipione, JJ Zhao, ... Open forum infectious diseases 8 (8), ofab371, 2021 | 39 | 2021 |
| Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary … KW Garey, J Jo, AJ Gonzales-Luna, B Lapin, A Deshpande, E Wang, ... JAMA Network Open 6 (1), e2253570-e2253570, 2023 | 18 | 2023 |
| Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial KW Garey, J McPherson, AQ Dinh, C Hu, J Jo, W Wang, CK Lancaster, ... Clinical Infectious Diseases 75 (7), 1164-1170, 2022 | 18 | 2022 |
| Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life RL Hengel, CP Schroeder, J Jo, TE Ritter, RV Nathan, AJ Gonzales-Luna, ... Journal of Patient-Reported Outcomes 6 (1), 49, 2022 | 9 | 2022 |
| Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings J Jo, AJ Gonzales-Luna, CK Lancaster, JK McPherson, K Begum, ... Anaerobe 75, 102543, 2022 | 5 | 2022 |
| Development of the invasive candidiasis discharge [I Can discharge] model: a mixed methods analysis J Jo, TT Tran, ND Beyda, D Simmons, JA Hendrickson, MS Almutairi, ... European Journal of Clinical Microbiology & Infectious Diseases 41 (10 …, 2022 | 2 | 2022 |
| Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies C Hu, W Wang, J Jo, KW Garey Journal of Chromatography B, 124057, 2024 | 1 | 2024 |
| Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile E Bassères, TA Eubank, K Begum, MJ Alam, J Jo, TM Le, CK Lancaster, ... Antimicrobial Agents and Chemotherapy, e01621-23, 2024 | 1 | 2024 |
| Significant publications on infectious diseases pharmacotherapy in 2021 N Nguyen, HC Chua, T Drake, J Jo, SA Stramel, NN Vuong, ... Journal of Pharmacy Practice 37 (1), 198-211, 2024 | 1 | 2024 |
| 489. Bile Acid Concentrations in Healthy Volunteers Receiving Oral Omadacycline or Vancomycin J Jo, C Hu, W Wang, AJ Gonzales-Luna, C Lancaster, KW Garey Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 547, 2022 | 1 | 2022 |
| Estimating Clostridioides difficile infection-associated readmission rates: A systematic review and meta-analysis TA Eubank, K Jantarathaneewat, J Jo, KW Garey Infection Control & Hospital Epidemiology, 1-5, 2024 | | 2024 |
| Erratum to “Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies”[J. Chromatogr. B 1236 (2024) 124057] C Hu, W Wang, J Jo, KW Garey Journal of Chromatography B 1241, 124166, 2024 | | 2024 |
| Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers J Jo, C Hu, K Begum, W Wang, TM Le, S Agyapong, BM Hanson, H Ayele, ... The Journal of Infectious Diseases 229 (1), 273-281, 2024 | | 2024 |
| 674. Host and Pathogen Risk Factors for Fulminant Clostridioides difficile Infection HC Chua, TA Eubank, J Jo, KW Garey, AJ Gonzales-Luna Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 736, 2023 | | 2023 |
| 277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects J Jo, S Agyapong, C Hu, W Wang, AJ Gonzales-Luna, C Lancaster, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 349, 2023 | | 2023 |
| Invesitgation of fecal pH in Healthy Volunteers Receiving Oral Omadacycline or Vancomycin S Agyapong, J Jo, C Lancaster, AJ Gonzales-Luna | | 2023 |
| 620. Pharmacokinetic-Pharmacodynamic Analysis of Oral Vancomycin and Gut Microbiome Changes in Healthy Volunteers: an Exploratory Study J Jo, J McPherson, AJ Gonzales-Luna, C Lancaster, KW Garey Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 672, 2022 | | 2022 |
| 157. A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins J Jo, J Hendrickson, M Almutairi, FS Alnezary, N Beyda, ... Open Forum Infectious Diseases 8 (Suppl 1), S189, 2021 | | 2021 |
| 18. Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings J Jo, AJ Gonzales-Luna, KW Garey Open Forum Infectious Diseases 8 (Suppl 1), S12, 2021 | | 2021 |
| 195. Antimicrobial Stewardship Incorporating New Antimicrobials for Use against Multi-Drug Resistant Pseudomonas aeruginosa in Cystic Fibrosis J Jo, AJ Gonzales-Luna, KW Garey Open Forum Infectious Diseases 7 (Supplement_1), S102-S102, 2020 | | 2020 |
